**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 79840

**Manuscript Type:** LETTER TO THE EDITOR

**Immunoglobulin G4 associated autoimmune cholangitis and pancreatitis and nivolumab**

Joob B *et al.* IgG4, cholangitis and pancreatitis and nivolumab

Beuy Joob, Viroj Wiwanitkit

**Beuy Joob,** Consultant, Sanitation1 Medical Academic Center, Bangkok 106000, Thailand

**Viroj Wiwanitkit,** Community Medicine, Dy Patil University, Pune 7439393, India

**Author contributions:** Joob B gave ideas, wrote, analyzed, revised and approved for final submission; Wiwanitkit V gave ideas, revised, supervised and approved for final submission.

**Corresponding author: Beuy Joob, PhD, Adjunct Professor, Senior Researcher,** Consultant, Sanitation1 Medical Academic Center, Bangkok, Bangkok 106000, Thailand. beuyjoob@hotmail.com

**Received:** September 8, 2022

**Revised:** October 18, 2022

**Accepted:** November 25, 2022

**Published online:**

**Abstract**

This letter to editor discussing on the publication on immunoglobulin G4 associated autoimmune cholangitis and pancreatitis following the administration of nivolumab. Concerns on confounding factors are raised and discussed.

**Key Words:** Immunoglobulin G4; autoimmune; Cholangitis; Pancreatitis; Nivolumab

Joob B, Wiwanitkit V. Immunoglobulin G4 associated autoimmune cholangitis and pancreatitis and nivolumab. *World J Clin Cases* 2022; In press

**Core Tip:** This letter to editor discussing on the publication on immunoglobulin G4 associated autoimmune cholangitis and pancreatitis following the administration of nivolumab. Concerns on confounding factors are raised and discussed.

**TO THE EDITOR**

We would like to share ideas on the publication “Immunoglobulin G4 associated autoimmune cholangitis and pancreatitis following the administration of nivolumab: A case report.” In a patient who had nivolumab treatment for anal squamous cell carcinoma, Agrawal *et al*[1] documented a case of immune-related pancreatitis and cholangiopathy. The patient's IgG4 Levels were normal at the time of presentation[1]. Nivolumab was probably what caused this case of IgG4-related cholangitis and pancreatitis, according to Agrawal *et al*[1].

We both believe that the clinical problem in this case may be related to the nivolumab. Recognizing the potential confounding impact of co-morbidity is necessary, though. For instance, a parasite infection may be the primary cause of pancreatitis and cholangitis in a tropical environment. For a conclusive diagnosis, a thorough study is required to rule out all alternative options[2]. It is challenging to draw a firm judgment without knowing the case's health or immune status prior to the injection of nivolumab.

In conclusion, IgG4-related cholangitis and pancreatitis developed after the administration of nivolumab, according to a case report that was mentioned. Nivolumab may have generated IgG4 Linked cholangitis and pancreatitis based on time course, however even pathologic evidence cannot prove the participation of IgG4-associated cholangitis and pancreatitis and nivolumab. In order to get a firm diagnosis, all potential treatments for comorbidities must be ruled out.

**REFERENCES**

1 **Agrawal R**, Guzman G, Karimi S, Giulianotti PC, Lora AJM, Jain S, Khan M, Boulay BR, Chen Y. Immunoglobulin G4 associated autoimmune cholangitis and pancreatitis following the administration of nivolumab: A case report. *World J Clin Cases* 2022; **10**: 7124-7129 [PMID: 36051149 DOI: 10.12998/wjcc.v10.i20.7124]

2 **Jani N**, Buxbaum J. Autoimmune pancreatitis and cholangitis. *World J Gastrointest Pharmacol Ther* 2015; **6**: 199-206 [PMID: 26558153 DOI: 10.4292/wjgpt.v6.i4.199]

**Footnotes**

**Conflict-of-interest statement:** The authors declare for no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** September 8, 2022

**First decision:** October 12, 2022

**Article in press:**

**Specialty type:** Immunology

**Country/Territory of origin:** Thailand

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Kaneko J; Notohara K, Japan **S-Editor:** Ma YJ **L-Editor:** A **P-Editor:** Ma YJ